Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems
Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
Tackling the Inevitability of Resistance One Genome at a Time
Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Defining FDA-Regulated Nanotech
FDA recently issued a draft guidance on whether an FDA-regulated product involves nanotechnology, followed by a 60-day comment period. During this time stakeholders expressed general support but also made their case for less red tape and more leeway; all the details can be read here. One major concern related to the agency’s definition of a nanomaterial. FDA had stated that it would ask (1) whether engineered materials and their end products have at least one dimension ranging from 1 to 100 nm, and (2) whether they exhibit physical or chemical properties or biological effects attributable to its dimensions even if they fall outside the nanoscale range, but going up to a maximum of one micrometer. Do you think these details are clear enough?